Skip to main content

Table 2 Antibiotic susceptibility testing of Isolated strains

From: A retrospective cross-sectional survey on nosocomial bacterial infections and their antimicrobial susceptibility patterns in hospitalized patients in northwest of Iran

(n%) Antibiotic susceptibility patterns

Bacterial isolates

  

SXT

GM

AN

NA

CRO

CP

FM

CN

E

G + 

S. aureus

S

3 (13.0%)

10 (43.5%)

16 (69.6%)

ND

ND

10 (43.5%)

ND

2 (8.7%)

0 (0%)

 

I

1 (4.3%)

9 (39.1%)

3 (13.0%)

ND

ND

3 (13.0%)

ND

6 (26.1%)

1 (4.3%)

 

R

19 (82.6%)

4 (17.4%)

4 (17.4%)

ND

ND

10 (43.5%)

ND

15 (65.2%)

22 (95.7%)

 

S. saprophyticus

S

3 (30.0%)

3 (30.0%)

9 (90.0%)

ND

ND

4 (40.0%)

ND

8 (80.0%)

2 (20.0%)

 

I

1 (10.0%)

4 (40.0%)

0 (0%)

ND

ND

3 (30.0%)

ND

1 (10.0%)

1 (10.0%)

 

R

6 (60.0%)

3 (30.0%)

1 (10.0%)

ND

ND

3 (30.0%)

ND

1 (10.0%)

7 (70.0%)

 

S. epidermidis

S

1 (12.5%)

5 (62.5%)

3 (37.5%)

ND

ND

3 (37.5%)

ND

3 (37.5%)

0 (0%)

 

I

0 (0%)

1 (12.5%)

0 (0%)

ND

ND

0 (0%)

ND

2 (25.0%)

0 (0%)

 

R

7 (87.5%)

2 (25.0%)

5 (62.5%)

ND

ND

5 (62.5%)

ND

3 (37.5%)

8 (100.0%)

 

E. faecalis

S

0 (0%)

1 (25.0%)

2 (50.0%)

ND

ND

0 (0%)

ND

0 (0%)

0 (0%)

 

I

0 (0%)

0 (0%)

0 (0%)

ND

ND

0 (0%)

ND

1 (25.0%)

0 (0%)

 

R

4 (100%)

3 (75.0%)

2 (50.0%)

ND

ND

4 (100.0%)

ND

3 (75.0)%

4 (100.0%)

 

E. faecalis

S

0 (0%)

2 (66.7%)

2 (66.7%)

ND

ND

2 (66.7%)

ND

2 (66.7%)

1 (33.3%)

 

I

0 (0%)

1 (33.3%)

0 (0%)

ND

ND

1 (33.3%)

ND

0 (0%)

0 (0%)

  

R

3 (100.0%)

0 (0%)

1 (33.3%)

ND

ND

0 (0%)

ND

1 (33.3%)

2 (66.7%)

G-

E. coli

S

122 (33.9%)

101 (28.1%)

ND

88 (24.4%)

189 (52.5%)

224 (62.2%)

198 (55.0%)

ND

ND

  

I

10 (2.8%)

195 (54.2%)

ND

45 (12.5%)

17 (4.7%)

16 (4.4%)

123 (34.2%)

ND

ND

  

R

228 (63.3%)

64 (17.8%)

ND

227 (63.1%)

154 (42.8%)

120 (33.3%)

39 (10.8%)

ND

ND

 

Citribacter spp

S

7 (28.0%)

11 (44.0%)

ND

0 (0%)

11 (44.0%)

16 (64.0%)

10 (40.0%)

ND

ND

  

I

2 (8.0%)

10 (40.0%)

ND

2 (8.0%)

2 (8.0%)

2 (8.0%)

12 (48.0%)

ND

ND

  

R

16 (64.0%)

4 (16.0%)

ND

23 (92.0%)

12 (48.0%)

7 (28.0%)

3 (12.0%)

ND

ND

 

Klebsiella spp

S

12 (27.3%)

10 (22.7%)

ND

6 (13.6%)

15 (34.1%)

27 (61.4%)

15 (34.1%)

ND

ND

  

I

4 (9.1%)

22 (50.0%)

ND

6 (13.6%)

1 (2.3%)

1 (2.3%)

6 (13.6%)

ND

ND

  

R

28 (63.6%)

12 (27.3%)

ND

32 (72.7%)

28 (63.6%)

16 (36.4%)

23 (52.3%)

ND

ND

 

Enterobacter spp

S

5 (31.2%)

5 (31.2%)

ND

1 (6.2%)

3 (18.8%)

9 (56.2%)

8 (50.0%)

ND

ND

  

I

2 (12.5%)

3 (18.8%)

ND

2 (12.5%)

2 (12.5%)

0 (0%)

4 (25.0%)

ND

ND

  

R

9 (56.2%)

8 (50.0%)

ND

13 (81.2%)

11 (68.8%)

7 (43.8%)

4 (25.0%)

ND

ND

 

Serratia

S

1 (100.0%)

0 (0%)

ND

0 (0%)

1 (100.0%)

1 (100.0%)

0 (0%)

ND

ND

  

I

0 (0%)

1 (100%)

ND

0 (0%)

0 (0%)

0 (0%)

1 (100.0%)

ND

ND

  

R

0 (0%)

0 (0%)

ND

1 (100.0%)

0 (0%)

0 (0)%

0 (0%)

ND

ND

 

Proteus spp

S

1 (50.0%)

1 (50.0%)

ND

0 (0%)

2 (100.0%)

2 (100.0%)

0 (0%)

ND

ND

  

I

0 (0%)

1 (50.0%)

ND

1 (50%)

0 (0%)

0 (0%)

0 (0%)

ND

ND

  

R

1 (50.0%)

0 (0%)

ND

1 (50%)

0 (0%)

0 (0%)

2 (100.0%)

ND

ND

 

P. aeruginosa

S

0 (0%)

2 (22.2%)

ND

0 (0%)

2 (22.2%)

4 (44.4%)

0 (0%)

ND

ND

  

I

0 (0%)

3 (33.3%)

ND

0 (0%)

2 (22.2%)

1 (11.1%)

0 (0%)

ND

ND

  

R

9 (100%)

4 (44.4%)

ND

9 (100.0%)

5 (55.6%)

4 (44.4%)

9 (100.0%)

ND

ND

 

Acinetobacter

S

0 (0%)

0 (0%)

ND

0 (0%)

0 (0%)

2 (66.7%)

1 (33.3%)

ND

ND

  

I

0 (0%)

2 (66.7%)

ND

0 (0%)

0 (0%)

2 (66.7%)

0 (0%)

ND

ND

  

R

3 (100%)

1 (33.3%)

ND

3 (100.0%)

3 (100.0%)

1 (33.1%)

2 (66.7%)

ND

ND

 

Shigella sonnei

S

0 (0%)

1 (100.0%)

ND

0 (0%)

1 (100.0%)

0 (0%)

0 (0%)

ND

ND

  

I

0 (0%)

0 (0%)

ND

0 (0%)

0 (0%)

0 (0%)

1 (100.0%)

ND

ND

  

R

1 (100.0%)

0 (0%)

ND

1 (100.0%)

0 (0%)

1 (100.0%)

0 (0%)

ND

ND

  1. G+ Gram positive bacteria, G− gram negative bacteria, S sensitive, I intermediate, R resistant, ND not determined, SXT cotrimoxazole, GM gentamycin, AN amikacin, NA nalidixic acid, CRO ceftriaxone, FM nitrofurantoin, CN cephalexin, E erythromycin